Researchers work to decipher genetic data in hunt for new prostate cancer treatments
They identified altered TGF‑β and Ran/mitotic spindle pathways in prostate cancer, suggesting new therapeutic targets for more personalized treatments
Florida State University researchers analyzed genomic data from prostate cancer patients, focusing on altered signaling pathways rather than individual genes. They highlighted aberrations in the TGF‑β and Ran/mitotic spindle pathways as potential targets for future therapies.
Identifying pathway‑level changes can streamline drug discovery, enabling more precise and effective treatments tailored to an individual’s tumor genetics.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience